2026 EAU前列腺癌指南更新:复发与转移性前列腺癌治疗
EAU-EANM-ESTRO-ESUR-ISUP-SIOG联合发布2026年前列腺癌指南更新,涵盖复发、转移性激素敏感性及去势抵抗性前列腺癌的治疗。专家组系统回顾2023-2025年新证据并为每条推荐新增推荐强度分级。治疗选择范围已扩大,包括ARPI、转移灶定向治疗、PARP抑制剂及其联合方案以及PSMA靶向治疗。
要点
- 复发风险分层可指导挽救性治疗决策
- 转移性前列腺癌治疗选择已显著拓宽,涵盖ARPI、PARP抑制剂及PSMA靶向治疗
- 指南推荐基于临床证据,未考虑各国成本、报销结构或资源可及性差异
核心结论
- 复发、转移性及去势抵抗性前列腺癌领域的证据正在快速演变,本指南反映了前列腺癌多学科管理的特性
研究设计与样本
- 制定机构为EAU联合EANM、ESTRO、ESUR、ISUP、SIOG的专家组
- 文献回顾时间范围为2023年至2025年
- 基于证据系统评价为每条推荐新增强度分级
- 全文可通过EAU指南办公室或uroweb.org获取
诊断标准与关键数值
- 复发前列腺癌风险分层可指导挽救性治疗决策
- 转移性前列腺癌治疗选项包括ARPI、转移灶定向治疗、PARP抑制剂及其联合方案以及PSMA靶向治疗
临床应用与阅片要点
- 复发患者先行风险分层再决定是否及如何进行挽救性治疗
- 转移性去势抵抗性前列腺癌可考虑PSMA靶向治疗等新型方案
- 应用指南推荐时需结合本地区成本、报销与资源条件考量
局限性
- 指南推荐未考虑不同医疗体系间成本、报销结构或资源可及性的差异
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVE: To present a summary of the 2026 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic hormone-sensitive and castration-resistant prostate cancer (PCa).
METHODS: The Panel performed a literature review of new data, covering the time frame between 2023 and 2025. The Guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.
KEY FINDINGS AND LIMITATIONS: Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. The range of treatment options for metastatic PCa has broadened, including androgen receptor pathway inhibitors (ARPI), metastasis-directed therapy, PARP inhibitors and their combinations, as well as PSMA-based therapy. The recommendations in the EAU Guidelines are based on clinical evidence and do not account for variations in cost, reimbursement structures, or resource availability across healthcare systems.
CONCLUSIONS AND CLINICAL IMPLICATIONS: The evidence in the field of relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These PCa Guidelines reflect the multidisciplinary nature of PCa management. A full version is available from the EAU Guidelines Office or online (http://uroweb.org/guideline/ prostate-cancer/).
引用
- Tilki, van den Bergh, Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2026. PMID: 42457456. doi:10.1016/j.eururo.2026.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。